These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35216344)

  • 1. In Vivo Metabolic Responses to Different Formulations of Amino Acid Mixtures for the Treatment of Phenylketonuria (PKU).
    Giarratana N; Giardino L; Bighinati A; Reiner G; Rocha JC
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.
    Solverson P; Murali SG; Brinkman AS; Nelson DW; Clayton MK; Yen CL; Ney DM
    Am J Physiol Endocrinol Metab; 2012 Apr; 302(7):E885-95. PubMed ID: 22297302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary Investigation to Review If a Glycomacropeptide Compared to L-Amino Acid Protein Substitute Alters the Pre- and Postprandial Amino Acid Profile in Children with Phenylketonuria.
    Daly A; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; MacDonald A
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria.
    Stroup BM; Nair N; Murali SG; Broniowska K; Rohr F; Levy HL; Ney DM
    J Nutr; 2018 Feb; 148(2):194-201. PubMed ID: 29490096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilisation of amino acid mixtures in adolescents with phenylketonuria.
    Mönch E; Herrmann ME; Brösicke H; Schöffer A; Keller M
    Eur J Pediatr; 1996 Jul; 155 Suppl 1():S115-20. PubMed ID: 8828625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino Acid Plasma Profiles from a Prolonged-Release Protein Substitute for Phenylketonuria: A Randomized, Single-Dose, Four-Way Crossover Trial in Healthy Volunteers.
    Scheinin M; Barassi A; Junnila J; Lovró Z; Reiner G; Sarkkinen E; MacDonald A
    Nutrients; 2020 Jun; 12(6):. PubMed ID: 32498426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model.
    Ahring KK; Dagnæs-Hansen F; Brüel A; Christensen M; Jensen E; Jensen TG; Johannsen M; Johansen KS; Lund AM; Madsen JG; Brøndum-Nielsen K; Pedersen M; Sørensen LK; Kjolby M; Møller LB
    PLoS One; 2022; 17(1):e0261150. PubMed ID: 35015767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimising amino acid absorption: essential to improve nitrogen balance and metabolic control in phenylketonuria.
    MacDonald A; Singh RH; Rocha JC; van Spronsen FJ
    Nutr Res Rev; 2019 Jun; 32(1):70-78. PubMed ID: 30284526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria.
    MacLeod EL; Clayton MK; van Calcar SC; Ney DM
    Mol Genet Metab; 2010 Aug; 100(4):303-8. PubMed ID: 20466571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU.
    Daly A; Evans S; Chahal S; Santra S; Pinto A; Jackson R; Gingell C; Rocha J; Van Spronsen FJ; MacDonald A
    Orphanet J Rare Dis; 2019 Feb; 14(1):44. PubMed ID: 30770754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria.
    Ney DM; Murali SG; Stroup BM; Nair N; Sawin EA; Rohr F; Levy HL
    Mol Genet Metab; 2017 Jun; 121(2):96-103. PubMed ID: 28400091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.
    Solverson P; Murali SG; Litscher SJ; Blank RD; Ney DM
    PLoS One; 2012; 7(9):e45165. PubMed ID: 23028819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine metabolism in health and disease: slow-release amino acids therapy improves tyrosine homeostasis in phenylketonuria.
    Porta F; Giorda S; Ponzone A; Spada M
    J Pediatr Endocrinol Metab; 2020 Dec; 33(12):1519-1523. PubMed ID: 33581706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Glycomacropeptide in Patients with Phenylketonuria: A Systematic Review and Meta-Analysis.
    Pena MJ; Pinto A; Daly A; MacDonald A; Azevedo L; Rocha JC; Borges N
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Three-Year Longitudinal Study Comparing Bone Mass, Density, and Geometry Measured by DXA, pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes.
    Daly A; Högler W; Crabtree N; Shaw N; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; Strauss BJ; Wilcox G; Fraser WD; Tang JCY; MacDonald A
    Nutrients; 2021 Jun; 13(6):. PubMed ID: 34204378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phenylketonuria patient: A recent dietetic therapeutic approach.
    Manta-Vogli PD; Dotsikas Y; Loukas YL; Schulpis KH
    Nutr Neurosci; 2020 Aug; 23(8):628-639. PubMed ID: 30359206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycomacropeptide in children with phenylketonuria: does its phenylalanine content affect blood phenylalanine control?
    Daly A; Evans S; Chahal S; Santra S; MacDonald A
    J Hum Nutr Diet; 2017 Aug; 30(4):515-523. PubMed ID: 28111827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria.
    Daly A; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; MacDonald A
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32899700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casein glycomacropeptide in phenylketonuria: does it bring clinical benefit?
    Daly A; Ilgaz F; Pinto A; MacDonald A
    Curr Opin Clin Nutr Metab Care; 2024 Jan; 27(1):31-39. PubMed ID: 38085662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective.
    Pena MJ; Pinto A; de Almeida MF; de Sousa Barbosa C; Ramos PC; Rocha S; Guimas A; Ribeiro R; Martins E; Bandeira A; Dias CC; MacDonald A; Borges N; Rocha JC
    Orphanet J Rare Dis; 2021 Feb; 16(1):84. PubMed ID: 33581730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.